Latest Imugene (ASX:IMU) News

Battery tech, biotech and balance-sheet repair drove the biggest gains this week, while guidance cuts and weak post-halt trading hurt several names. Deal-making and fresh equity funding stayed busy, especially in rare earths, defence and gold.

Imugene, Vitasora and Adherium led a volatile week in healthcare shares, as trial news and software rollouts battled capital raisings, legal issues and weak sentiment in smaller biotech names. Big contracts, takeover steps and record earnings kept the sector busy, but several stocks still fell even after reporting clear operational progress.

Imugene Limited’s allogeneic CAR T therapy, azer-cel, delivered an 81% overall response rate in a Phase 1b trial cohort of CAR T-naïve patients with various CD19 B-cell malignancies, with updated data due at ASCO 2026.

A brutal split opened up in small caps: a few stocks surged on hard approvals and funding, while many resource names slid even after announcing big numbers. The week’s tape looked simple: investors paid for certainty and sold anything that still needs time, permits, or more cash.

A handful of small caps did the heavy lifting this week, led by a lung cancer trial green light and a steep sell-off after a capital raise. Investors paid up for clear clinical steps, but punished dilution and stocks that reopened lower and kept sliding.

Imugene Limited has launched a $20 million equity raising comprising a $12 million placement and an $8 million Share Purchase Plan, alongside issuing options, convertible notes, and warrants to support its azer-cel clinical program.

A single biotech result reset expectations in minutes, while gold and critical minerals kept investors busy on deals, drilling and funding. The week’s biggest moves came from one trial being stopped, a miner losing altitude after heavy selling, and a U.S. tungsten stock hit hard on risk-off trading.

A brutal clinical trial stop wiped out Immutep, while Adherium surged on faster Remote Patient Monitoring growth. Across the rest of healthcare, investors paid up for proof: accredited tests, enrolled Phase III studies, and signed multi-year contracts.

Imugene Limited has launched a $20 million capital raising through a $12 million institutional placement and an $8 million Share Purchase Plan, alongside a convertible notes amendment to support its clinical development pipeline.

Imugene Limited reports striking early results from its Phase 1b azer-cel trial, achieving a 100% overall response rate in chronic lymphocytic leukemia and 80% in marginal zone lymphoma, while broadening its study to include a BTK inhibitor combination.

Cannabis and psychedelics delivered the week’s biggest winner, while a cluster of smaller caps slid on fresh losses, leadership change, and near-term uncertainty. Investors kept paying up for FDA clearances and reimbursement wins, but punished businesses where early pops quickly disappeared.

Imugene Limited reports a narrower half-year loss as it advances its promising azer-cel CAR T therapy with strong clinical results and FDA backing, supported by a $25 million capital raise.